Spotlight: Advance Biotech Grant Program

Unlock your molecule’s potential. Apply to the US and Canada Advance Biotech Grant Program Your promising molecule requires resources and support to realize it’s potential. Our Advance Biotech Grant Program, 6th edition, is open to biotech start-up companies in US and Canada to help you accelerate to clinic faster. Apply now for a chance to win [...]

February 1st, 2019|

Spotlight: Biotech Companies in the “Big 3” Regions Rake in the Cash

  BioWeekSF will soon be here again — January 5-10, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation, the week’s premium online guide,, is showcasing a series of reports and other resources focusing on financing and dealmaking. This feature is from DealForma, the biopharma database providing you [...]

November 13th, 2018|

Spotlight: What Small and Emerging Companies Need When Entering Into Dealmaking Discussions

BioWeekSF will soon be here again -- January 6-11, 2019 -- the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation,  the week's premium online guide,, is sponsoring a series of viewpoints and more from leaders and professionals involved in life sciences/healthcare dealmaking. As Chair of Foley Hoag's Licensing & [...]

October 14th, 2018|

MassBio’s 2018 Industry Snapshot – Boston/Cambridge Leads the Way

Introduction of press release from MassBio: "August 29 - The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, which shows that Massachusetts biotechs dominated the IPO market in 2017, accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016. 2018 has already outpaced 2017 in terms of total Massachusetts IPOs [...]

September 3rd, 2018|

Spotlight: First Coast Tech Hubs Gather @ RESI Boston

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series The First Coast Innovator’s Gathering is a new component of the Redefining Early Stage Investments (RESI) Conference Series which was requested by the investors and strategic channel partners who routinely attend RESI. Many of these partners wanted LSN to bring the “earliest stage” [...]

August 23rd, 2018|

May Financial Focus: Boston Area a Hot-Bed for Biopharma Startups

By Marie Daghlian VC funding for Boston area biotech companies is on fire and its momentum shows no signs of slowing up. Boston area biotech and health-related companies raised $1.58 billion in 32 deals in the first quarter of 2018. That compares favorably with the $1.59 billion raised in Q4 2017 in 42 deals, and [...]

May 14th, 2018|

Latest Startup From Harvard’s Springer Gets $51.5M

From press release: "Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the clinic. The round was co-led by SR One and Pfizer Venture Investments, joined by Omega Funds and AbbVie Ventures. They join [...]

June 30th, 2016|

Medtronic to Acquire HeartWare in $1.1B Deal

Intro of HeartWare press release: "Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in [...]

June 27th, 2016|

Life In The Trenches Of A Biotech LLC

Jeb Keiper, CBO of Nimbus Therapeutics LLC, has written a great blogpost (as part of the "From The Trenches" feature of LifeSciVC) about corporate financing, program-focused subsidiaries, the differences between "inc." and "llc", and much more. The intro: "Unsurprisingly, I had not given that much thought to the parent entity of my new employer when [...]

June 21st, 2016|

How to Pay for Cutting-Edge Drugs?

In the feature "Promising gene therapies pose million-dollar conundrum," Erika Check Hayden/Nature details how stakeholders in various segments of the life sciences and healthcare are trying to wrangle through the financial/pricing knots of gene therapies. The intro: "Drugs that act by modifying a patient’s genes are close to approval in the United States, and one is already available in [...]

June 15th, 2016|